Circulating Cytokines as Predictors of Radiation Induced Pulmonary Toxicity

Study summary

This study is being conducted by the University of Rochester Cancer Center to determine the levels of cytokines in the blood, and to determine if blood levels of these cytokines are related to the side effects of radiation therapy combined with other treatments.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forLung Neoplasms

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 14, 2017 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?University of Rochester

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: University of Rochester
Interventions being studied: Not specified

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Radiation therapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Patients receiving radiation therapy for lung cancer combined with surgery either pre or post RT to the chest for lung cancer not associated with atelectasis, pleural effusion. Patients receiving HDR Brachytherapy for lung cancer. Patients receiving concomitant radiation and interferon therapy for lung cancer. Patients receiving concomitant chemotherapy and radiation for lung cancer. Prior drug therapy does not make patients ineligible. Karnofsky ≥ 70 %. There are no age restrictions. Acceptable bone marrow function - WBC 2 3000/mm3, platelet count \> 100,000, hematocrit ≥ 33%, hemoglobin ≥ 11 gms/dl. Life expectancy \> 6 months. Patients must sign informed consent meeting all federal and institutional guidelines.

Reasons someone may not be able to joinExclusion criteria

Patients not meeting eligibility criteria stated above

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University of Rochester, Dept. Radiation OncologyRochester, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 14, 2017. Always confirm current availability with the study team.

View original record ↗